TGFBI expression is associated with a better response to chemotherapy in NSCLC

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Irigoyen, Marta ^a   Pajares, María J ^a   Agorreta, Jackeline ^a   Ponz Sarvisé, Mariano ^b   Salvo, Elisabeth ^a   Lozano, María D ^b   Pío, Ruben ^a   Gil Bazo, Ignacio ^b   Rouzaut, Ana ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA INDUCED PROTEIN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ANTINEOPLASTIC AGENT; BETAIG H3 PROTEIN; BETAIG-H3 PROTEIN; CASPASE; SCLEROPROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MOLECULAR SIZE; PROTEIN PROTEIN INTERACTION; TRANSIENT EXPRESSION; LUNG TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASES; ENZYME ACTIVATION; EXTRACELLULAR MATRIX PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; PROGNOSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 77952681430     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-130     Document Type: Article

References (46)

1. Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 1989, 8:98-101.
2. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003, 3:453-8. 10.1038/nrc1098, 12778135.
3. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004, 4:839-49. 10.1038/nrc1477, 15516957.
4. Vincent TL, Gatenby RA. An evolutionary model for initiation, promotion, and progression in carcinogenesis. Int J Oncol 2008, 32:729-737.
5. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17:463-516. 10.1146/annurev.cellbio.17.1.463, 2792593, 11687497.
6. Moschos SJ, Drogowski LM, Reppert SL, Kirkwood JM. Integrins and cancer. Oncology (Williston Park) 2007, 9(Suppl 3):13-20.
7. Skonier J, Neubauer M, Madisen L, Bennett K, Plowman GD, Purchio AF. cDNA cloning and sequence analysis of beta ig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-beta. DNA Cell Biol 1992, 11:511-22. 10.1089/dna.1992.11.511, 1388724.
8. Thapa N, Lee BH, Kim IS. TGFBIp/betaig-h3 protein: a versatile matrix molecule induced by TGF-beta. Int J Biochem Cell Biol 2007, 39:2183-94. 10.1016/j.biocel.2007.06.004, 17659994.
9. Kim JE, Kim SJ, Lee BH, Park RW, Kim KS, Kim IS. Identification of motifs for cell adhesion within the repeated domains of transforming growth factor-beta-induced gene, betaig-h3. J Biol Chem 2000, 275:30907-15. 10.1074/jbc.M002752200, 10906123.
10. Kitahara O, Furukawa Y, Tanaka T, Kihara C, Ono K, Yanagawa R, Nita ME, Takagi T, Nakamura Y, Tsunoda T. Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. Cancer Res 2001, 61:3544-9.
11. Ivanov SV, Ivanova AV, Salnikow K, Timofeeva O, Subramaniam M, Lerman MI. Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors. Biochem Biophys Res Commun 2008, 370:536-40. 10.1016/j.bbrc.2008.03.066, 2413015, 18359287.
12. Matsuda D, Khoo SK, Massie A, Iwamura M, Chen J, Petillo D, Wondergem B, Avallone M, Kloostra SJ, Tan MH, et al. Identification of copy number alterations and its association with pathological features in clear cell and papillary RCC. Cancer Lett 2008, 272:260-7. 10.1016/j.canlet.2008.06.015, 18682315.
13. Schneider D, Kleeff J, Berberat PO, Zhu Z, Korc M, Friess H, Büchler MW. Induction and expression of betaig-h3 in pancreatic cancer cells. Biochim Biophys Acta 2002, 1588:1-6.
14. Becker J, Volland S, Noskova I, Schramm A, Schweigerer LL, Wilting J. Keratoepithelin reverts the suppression of tissue factor pathway inhibitor 2 by MYCN in human neuroblastoma: a mechanism to inhibit invasion. Int J Oncol 2008, 32:235-40.
15. Calaf GM, Echiburu-Chau C, Zhao YL, Hei TK. BigH3 protein expression as a marker for breast cancer. Int J Mol Med 2008, 21:561-8.
16. Ma C, Rong Y, Radiloff DR, Datto MB, Centeno B, Bao S, Cheng AW, Lin F, Jiang S, Yeatman TJ, Wang XF. Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. Genes Dev 2008, 22:308-21. 10.1101/gad.1632008, 2216691, 18245446.
17. Zhang Y, Wen G, Shao G, Wang C, Lin C, Fang H, Balajee AS, Bhagat G, Hei TK, Zhao Y. TGFBI deficiency predisposes mice to spontaneous tumor development. Cancer Res 2009, 69:37-44. 10.1158/0008-5472.CAN-08-1648, 2664305, 19117985.
18. Zhao YL, Piao CQ, Hei TK. Downregulation of Betaig-h3 gene is causally linked to tumorigenic phenotype in asbestos treated immortalized human bronchial epithelial cells. Oncogene 2002, 21:7471-7. 10.1038/sj.onc.1205891, 12386809.
19. Zhao YL, Piao CQ, Hei TK. Tumor suppressor function of Betaig-h3 gene in radiation carcinogenesis. Adv Space Res 2003, 31:1575-82. 10.1016/S0273-1177(03)00094-2, 12971413.
20. Zhao Y, El-Gabry M, Hei TK. Loss of Betaig-h3 protein is frequent in primary lung carcinoma and related to tumorigenic phenotype in lung cancer cells. Mol Carcinog 2006, 45:84-92. 10.1002/mc.20167, 16329146.
21. Shah JN, Shao G, Hei TK, Zhao Y. Methylation screening of the TGFBI promoter in human lung and prostate cancer by methylation-specific PCR. BMC Cancer 2008, 8:284. 10.1186/1471-2407-8-284, 2572632, 18834524.
22. Ahmed AA, Mills AD, Ibrahim AE, Temple J, Blenkiron C, Vias M, Massie CE, Iyer NG, McGeoch A, Crawford R, et al. The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell 2007, 12:514-27. 10.1016/j.ccr.2007.11.014, 2148463, 18068629.
23. Cheresh DA, Stupack DG. Regulation of angiogenesis: apoptotic cues from the ECM. Oncogene 2008, 27:6285-98. 10.1038/onc.2008.304, 18931694.
24. Kim JE, Kim SJ, Jeong HW, Lee BH, Choi JY, Park RW, Park JY, Kim IS. RGD peptides released from beta ig-h3, a TGF-beta-induced cell-adhesive molecule, mediate apoptosis. Oncogene 2003, 22:2045-53. 10.1038/sj.onc.1206269, 12673209.
25. Stupack DG, Puente XS, Souphaphone B, Storgard CM, Cheresh DA. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol 2001, 155:459-470. 10.1083/jcb.200106070, 2150834, 11684710.
26. Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol 2008, 3:819-31. 10.1097/JTO.0b013e31818020eb, 18670299.
27. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics 2008. CA Cancer J Clin 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
28. Zutter MM. Integrin-mediated adhesion: tipping the balance between chemosensitivity and chemoresistance. Adv Exp Med Biol 2007, 608:87-100. full_text, 17993234.
29. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007, 99:1441-54. 10.1093/jnci/djm135, 17895480.
30. Bernstein LR, Liotta LA. Molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis. Curr Opin Oncol 1994, 6:106-13. 10.1097/00001622-199401000-00015, 7515692.
31. Lee BH, Bae JS, Park RW, Kim JE, Park JY, Kim IS. betaig-h3 triggers signaling pathways mediating adhesion and migration of vascular smooth muscle cells through alphavbeta5 integrin. Exp Mol Med 2006, 38:153-61.
32. Bae JS, Lee SH, Kim JE, Choi JY, Park RW, Yong Park J, Park HS, Sohn YS, Lee DS, Bae Lee E, et al. Betaig-h3 supports keratinocyte adhesion, migration, and proliferation through alpha3beta1 integrin. Biochem Biophys Res Commun 2002, 294:940-8. 10.1016/S0006-291X(02)00576-4, 12074567.
33. Jeong HW, Kim IS. TGF-beta1 enhances betaig-h3-mediated keratinocyte cell migration through the alpha3beta1 integrin and PI3K. J Cell Biochem 2004, 92:770-80. 10.1002/jcb.20110, 15211574.
34. Nam JO, Kim JE, Jeong HW, Lee SJ, Lee BH, Choi JY, Park RW, Park JY, Kim IS. Identification of the alphavbeta3 integrin-interacting motif of betaig-h3 and its anti-angiogenic effect. J Biol Chem 2003, 278:25902-9. 10.1074/jbc.M300358200, 12704192.
35. Irigoyen M, Anso E, Salvo E, de las Herrerias JD, Martinez-Irujo JJ, Rouzaut A. TGFbeta-induced protein mediates lymphatic endothelial cell adhesion to the extracellular matrix under low oxygen conditions. Cell Mol Life Sci 2008, 65:2244-55. 10.1007/s00018-008-8071-9, 18560760.
36. Morand S, Buchillier V, Maurer F, Bonny C, Arsenijevic Y, Munier FL, Schorderet DF. Induction of apoptosis in human corneal and HeLa cells by mutated BIGH3. Invest Ophthalmol Vis Sci 2003, 44:2973-9. 10.1167/iovs.02-0661, 12824240.
37. Perlot RL, Shapiro IM, Mansfield K, Adams CS. Matrix regulation of skeletal cell apoptosis II: role of Arg-Gly-Asp-containing peptides. J Bone Miner Res 2002, 17:66-76. 10.1359/jbmr.2002.17.1.66, 11771671.
38. Gong W, Liu Y, Huang B, Lei Z, Wu FH, Li D, Feng ZH, Zhang GM. Recombinant CBD-HepII polypeptide of fibronectin inhibits alphavbeta3 signaling and hematogenous metastasis of tumor. Biochem Biophys Res Commun 2008, 367:144-9. 10.1016/j.bbrc.2007.12.110, 18162175.
39. Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennnings NB, Kinch MS, et al. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia 2008, 10:1259-67. 2570602, 18953435.
40. Simon GR, Begum M, Bepler G. Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer. Future Oncol 2008, 4:51-9. 10.2217/14796694.4.1.51, 18241000.
41. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001, 18:1059-68. 10.1183/09031936.01.00275301, 11829087.
42. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK) Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Br J Cancer 2005, 93(4):387-9. 10.1038/sj.bjc.6602678, 2361579, 16106245.
43. Cortes J, Rodriguez J, Diaz-Gonzalez JA, Garzon C, Gurpide A, Arbea L, Gil-Bazo I, Navarro V, Cambeiro M, Nicolas AI, et al. Comparison of unidimensional and bidimensional measurements in metastatic non-small cell lung cancer. Br J Cancer 2002, 87(2):158-60. 10.1038/sj.bjc.6600449, 2376101, 12107835.
44. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-47. 10.1016/j.ejca.2008.10.026, 19097774.
45. Camp RL, Rimm EB, Rimm DL. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 1999, 86:2259-65. 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2, 10590366.
46. Irigoyen M, Anso E, Martinez E, Garayoa M, Martinez-Irujo JJ, Rouzaut A. Hypoxia alters the adhesive properties of lymphatic endothelial cells. A transcriptional and functional study. Biochim Biophys Acta 2007, 1773:880-90. 10.1016/j.bbamcr.2007.03.001, 17442415.